WUXIF News and Press, Wuxi AppTec Co. Ltd. - Class H From 03/31/21

Healthcare was the second-best performing sector in China in 2020. The immediate healthcare needs stemming from the pandemic, together with the emergence of green shoots in biotech innovation, paved the way for a landmark year in the development of China’s healthcare system. ...

The Asia Partners series of funds invests primarily in China and India, from venture capital through growth stage for biotech, pharma, medical device, diagnostic and healthcare companies. WuXi AppTec, a China-global CRO/CMO, paid $135 million to acquire Oxgene, a UK CDMO that develops...

China Grand Pharma announced a $340 million agreement to develop and commercialize Telix Pharma's molecularly-targeted radiation products in China. JW Therapeutics, a Shanghai cell therapy company, raised $300 million in its Hong Kong IPO at a market capitalization of $1 billion. ...

Deals and Financings Suzhou Innovent Bio (IVBIY) [HK:01801] expanded its 2015 alliance with Eli Lilly (LLY) for Tyvyt ® , Innovent's anti-PD-1 immunotherapy (see story ). In return for a $1+ billion package, Lilly will have an exclusive license to develop Tyvyt in ex-China markets. Lil...

WuXi AppTec ( OTCPK:WUXIF ) : Q2 Non-GAAP EPS of RMB0.41; GAAP EPS of RMB0.61. More news on: WuXi AppTec Co., Ltd., WUXI APPTEC CO UNSP/ADR, Earnings news and commentary, Read more ...